- 专利标题: 4'-phosphate analogs and oligonucleotides comprising the same
-
申请号: US16328546申请日: 2017-09-01
-
公开(公告)号: US11414659B2公开(公告)日: 2022-08-16
- 发明人: Weimin Wang , Qingyi Li , Naim Nazef
- 申请人: Dicerna Pharmaceuticals, Inc.
- 申请人地址: US MA Lexington
- 专利权人: Dicerna Pharmaceuticals, Inc.
- 当前专利权人: Dicerna Pharmaceuticals, Inc.
- 当前专利权人地址: US MA Lexington
- 代理机构: MH2 Technology Law Group, LLP
- 国际申请: PCT/US2017/049909 WO 20170901
- 国际公布: WO2018/045317 WO 20180308
- 主分类号: A01N43/04
- IPC分类号: A01N43/04 ; A61K31/70 ; C12N15/113 ; C07H21/04 ; C07H19/10 ; C07H21/02 ; A61K31/712 ; A61K47/54 ; A61K31/7125 ; A61K45/06 ; A61K47/60 ; A61K31/7115
摘要:
Disclosed herein are oligonucleotides, such as nucleic acid inhibitor molecules, having a 4′-phosphate analog and methods of using the same, for example, to modulate the expression of a target gene in a cell. The oligonucleotide of the disclosure comprises a 5′-terminal nucleotide represented by Formula III: wherein Ra, Rb, B, X2 and Y are as defined in the specification. The phosphate analogs are bound to the 4′-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog thereof) of the 5′-terminal nucleotide of an oligonucleotide. Typically, the phosphate analog is an oxymethylphosphonate, where the oxygen atom of the oxymethyl group is bound to the 4′-carbon of the sugar moiety or analog thereof. An illustrative 5′-terminal nucleotide of an oligonucleotide of the disclosure may have the following chemical structure:
公开/授权文献
信息查询
IPC分类: